3 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun ...
Voir le projet
11
Participants partenaires
TERMINÉ
Clinical validation of the CD32b biomarker on the European market (BI-MARK)
Date du début: 1 mai 2015, Date de fin: 30 sept. 2015,
The overall objective of the proposed project is the clinical validation of a novel biomarker for B-cell malignancies. The presently most widely used anti-CD20 antibody treatment rituximab has considerably improved treatment options for patients with B-cell malignancies. However, effectiveness is limited by resistance to rituximab and reduced response on repeated treatments. Data indicates that tu ...
Voir le projet
1
Participant partenaire
TERMINÉ
European Consortium for Anticancer Antibody Development (EUCAAD)
Date du début: 1 mai 2008, Date de fin: 30 avr. 2012,
Cancer is the second leading cause of death in European countries, and one of the most imminent health problems in the developed world. Innovative, so-called targeted therapies are urgently needed that aim specifically at cancer cells or to cells of the stroma that support tumor growth. The ultimate goal of a targeted therapy is to increase anti-tumor efficacy with lowest possible side effects. R ...
Voir le projet